Literature DB >> 11102648

Vasopressinergic regulation of the hypothalamic-pituitary-adrenal axis: implications for stress adaptation.

G Aguilera1, C Rabadan-Diehl.   

Abstract

In addition to its role on water conservation, vasopressin (VP) regulates pituitary ACTH secretion by potentiating the stimulatory effects of corticotropin releasing hormone (CRH). The pituitary actions of VP are mediated by plasma membrane receptors of the V1b subtype, coupled to calcium-phospholipid signaling systems. VP is critical for adaptation of the hypothalamic-pituitary-adrenal (HPA) axis to stress as indicated by preferential expression of VP over CRH in parvocellular neurons of the hypothalamic paraventricular nucleus, and the upregulation of pituitary VP receptors during stress paradigms associated with corticotroph hyperresponsiveness. V1b receptor mRNA levels and coupling of the receptor to phospolipase C are stimulated by glucocorticoids, effects which may contribute to the refractoriness of VP-stimulated ACTH secretion to glucocorticoid feedback. The data suggest that vasopressinergic regulation of the HPA axis is critical for sustaining corticotroph responsiveness in the presence of high circulating glucocorticoid levels during chronic stress.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11102648     DOI: 10.1016/s0167-0115(00)00196-8

Source DB:  PubMed          Journal:  Regul Pept        ISSN: 0167-0115


  83 in total

Review 1.  Vasopressin and alcohol: a multifaceted relationship.

Authors:  Kathryn M Harper; Darin J Knapp; Hugh E Criswell; George R Breese
Journal:  Psychopharmacology (Berl)       Date:  2018-11-03       Impact factor: 4.530

Review 2.  Neuropeptide receptor ligands as drugs for psychiatric diseases: the end of the beginning?

Authors:  Guy Griebel; Florian Holsboer
Journal:  Nat Rev Drug Discov       Date:  2012-05-18       Impact factor: 84.694

Review 3.  The hypothalamic-pituitary-adrenal axis and serotonin abnormalities: a selective overview for the implications of suicide prevention.

Authors:  Maurizio Pompili; Gianluca Serafini; Marco Innamorati; Anne Maria Möller-Leimkühler; Giancarlo Giupponi; Paolo Girardi; Roberto Tatarelli; David Lester
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2010-02-20       Impact factor: 5.270

4.  Selectivity of d[Cha4]AVP and SSR149415 at human vasopressin and oxytocin receptors: evidence that SSR149415 is a mixed vasopressin V1b/oxytocin receptor antagonist.

Authors:  Cristiana Griffante; Andrew Green; Ornella Curcuruto; Carl P Haslam; Bryony A Dickinson; Roberto Arban
Journal:  Br J Pharmacol       Date:  2005-11       Impact factor: 8.739

5.  The Vasopressin 1b Receptor Antagonist A-988315 Blocks Stress Effects on the Retrieval of Object-Recognition Memory.

Authors:  Areg Barsegyan; Piray Atsak; Wilfried B Hornberger; Peer B Jacobson; Marcel M van Gaalen; Benno Roozendaal
Journal:  Neuropsychopharmacology       Date:  2015-02-11       Impact factor: 7.853

6.  Effects of social isolation on mRNA expression for corticotrophin-releasing hormone receptors in prairie voles.

Authors:  Hossein Pournajafi-Nazarloo; Leila Partoo; Jason Yee; Jennifer Stevenson; Lisa Sanzenbacher; William Kenkel; Seyed Ramezan Mohsenpour; Kozo Hashimoto; C Sue Carter
Journal:  Psychoneuroendocrinology       Date:  2010-11-20       Impact factor: 4.905

Review 7.  Stress physiology in marine mammals: how well do they fit the terrestrial model?

Authors:  Shannon Atkinson; Daniel Crocker; Dorian Houser; Kendall Mashburn
Journal:  J Comp Physiol B       Date:  2015-04-26       Impact factor: 2.200

8.  Stable modifications to the expression of neurohormones in the rat hypothalamus in a model of post-traumatic stress disorder.

Authors:  V I Mironova; E A Rybnikova
Journal:  Neurosci Behav Physiol       Date:  2009-12-11

9.  SSR149415, a non-peptide vasopressin V1b receptor antagonist, has long-lasting antidepressant effects in the olfactory bulbectomy-induced hyperactivity depression model.

Authors:  M E Breuer; M M van Gaalen; W Wernet; S E F Claessens; R S Oosting; B Behl; S M Korte; H Schoemaker; G Gross; B Olivier; L Groenink
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-07-31       Impact factor: 3.000

Review 10.  Trends in the development of new antidepressants. Is there a light at the end of the tunnel?

Authors:  Pal Pacher; Valeria Kecskemeti
Journal:  Curr Med Chem       Date:  2004-04       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.